Roivant Sciences Ltd. - Net Worth and Insider Trading

Roivant Sciences Ltd. Net Worth

The estimated net worth of Roivant Sciences Ltd. is at least $3.9 Billion dollars as of 2024-11-29. Roivant Sciences Ltd. is the Director, 10% Owner of Immunovant Inc and owns about 79,805,331 shares of Immunovant Inc (IMVT) stock worth over $2.3 Billion. Roivant Sciences Ltd. is the 10% Owner of Myovant Sciences Ltd and owns about 45,008,604 shares of Myovant Sciences Ltd (MYOV) stock worth over $1.2 Billion. Roivant Sciences Ltd. is also the 10% Owner of Urovant Sciences Ltd and owns about 22,860,013 shares of Urovant Sciences Ltd (UROV) stock worth over $371 Million. Besides these, Roivant Sciences Ltd. also holds Sio Gene Therapies Inc (SIOX) . Details can be seen in Roivant Sciences Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Roivant Sciences Ltd. has not made any transactions after 2023-10-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Roivant Sciences Ltd.

Roivant Sciences Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Roivant Sciences Ltd. owns 6 companies in total, including Immunovant Inc (IMVTU) , Sio Gene Therapies Inc (SIOX) , and Myovant Sciences Ltd (MYOV) among others .

Click here to see the complete history of Roivant Sciences Ltd.’s form 4 insider trades.

Insider Ownership Summary of Roivant Sciences Ltd.

Ticker	Comapny	Transaction Date	Type of Owner
IMVTU	Immunovant Inc	2020-09-17	10 percent owner
SIOX	Sio Gene Therapies Inc	2020-02-24	10 percent owner
MYOV	Myovant Sciences Ltd	2019-12-17	10 percent owner
		2019-12-27	10 percent owner
		2021-10-18	10 percent owner
		2023-10-02	10 percent owner

Roivant Sciences Ltd. Latest Holdings Summary

Roivant Sciences Ltd. currently owns a total of 4 stocks. Among these stocks, Roivant Sciences Ltd. owns 79,805,331 shares of Immunovant Inc (IMVT) as of October 2, 2023, with a value of $2.3 Billion and a weighting of 58.98%. Roivant Sciences Ltd. owns 45,008,604 shares of Myovant Sciences Ltd (MYOV) as of December 17, 2019, with a value of $1.2 Billion and a weighting of 31.24%. Roivant Sciences Ltd. also owns 22,860,013 shares of Urovant Sciences Ltd (UROV) as of June 19, 2019, with a value of $371 Million and a weighting of 9.55%. The other 1 stocks Sio Gene Therapies Inc (SIOX) have a combined weighting of 0.23% among all his current holdings.

Latest Holdings of Roivant Sciences Ltd.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
IMVT	Immunovant Inc	2023-10-02	79,805,331	28.73	2,292,807,160
MYOV	Myovant Sciences Ltd	2019-12-17	45,008,604	26.98	1,214,332,136
UROV	Urovant Sciences Ltd	2019-06-19	22,860,013	16.24	371,246,611
SIOX	Sio Gene Therapies Inc	2020-02-24	18,577,380	0.48	8,879,988

Holding Weightings of Roivant Sciences Ltd.

Roivant Sciences Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Roivant Sciences Ltd. has made a total of 4 transactions in Immunovant Inc (IMVT) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Immunovant Inc is the acquisition of 1,526,316 shares on October 2, 2023, which cost Roivant Sciences Ltd. around $58 Million.

According to the SEC Form 4 filings, Roivant Sciences Ltd. has made a total of 2 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Myovant Sciences Ltd is the acquisition of 245,000 shares on December 17, 2019, which cost Roivant Sciences Ltd. around $4 Million.

According to the SEC Form 4 filings, Roivant Sciences Ltd. has made a total of 0 transactions in Urovant Sciences Ltd (UROV) over the past 5 years. The most-recent trade in Urovant Sciences Ltd is the acquisition of 18,204 shares on June 19, 2019, which cost Roivant Sciences Ltd. around $151,457.

More details on Roivant Sciences Ltd.'s insider transactions can be found in the Insider Trading History of Roivant Sciences Ltd. table.

Insider Trading History of Roivant Sciences Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Roivant Sciences Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Roivant Sciences Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Roivant Sciences Ltd. is 4.81%. GuruFocus also compares Roivant Sciences Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Roivant Sciences Ltd. within 3 months outperforms 13 times out of 23 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Roivant Sciences Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Roivant Sciences Ltd.

Average Return

Average return per transaction

Outperforming Transactions

15 out of 23 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	0.68
Relative Return to S&P 500(%)	-1.07

Roivant Sciences Ltd. Ownership Network

Ownership Network List of Roivant Sciences Ltd.

No Data

Ownership Network Relation of Roivant Sciences Ltd.

Roivant Sciences Ltd. Owned Company Details

What does Immunovant Inc do?

Who are the key executives at Immunovant Inc?

Roivant Sciences Ltd. is the 10 percent owner of Immunovant Inc. Other key executives at Immunovant Inc include Chief Dev. & Tech. Officer Julia G. Butchko , Chief Scientific Officer Michael James Elliott , and director & Chief Executive Officer Peter Salzmann .

Immunovant Inc (IMVTU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immunovant Inc (IMVTU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunovant Inc (IMVTU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunovant Inc (IMVTU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunovant Inc Insider Transactions

No Available Data

What does Sio Gene Therapies Inc do?

Who are the key executives at Sio Gene Therapies Inc?

Roivant Sciences Ltd. is the 10 percent owner of Sio Gene Therapies Inc. Other key executives at Sio Gene Therapies Inc include Chief Commercial Officer Parag V Meswani , Chief Executive Officer Pavan Cheruvu , and Principal Financial Officer David W. Nassif .

Sio Gene Therapies Inc (SIOX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sio Gene Therapies Inc (SIOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sio Gene Therapies Inc (SIOX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sio Gene Therapies Inc (SIOX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sio Gene Therapies Inc Insider Transactions

No Available Data

What does Myovant Sciences Ltd do?

Who are the key executives at Myovant Sciences Ltd?

Roivant Sciences Ltd. is the 10 percent owner of Myovant Sciences Ltd. Other key executives at Myovant Sciences Ltd include 10 percent owner Sumitomo Chemical Co., Ltd. , Chief Commercial Officer Lauren Merendino , and General Counsel & Corp. Secy. Matthew Lang .

Myovant Sciences Ltd (MYOV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Myovant Sciences Ltd (MYOV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Myovant Sciences Ltd (MYOV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Myovant Sciences Ltd (MYOV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Myovant Sciences Ltd Insider Transactions

No Available Data

What does Urovant Sciences Ltd do?

Who are the key executives at Urovant Sciences Ltd?

Roivant Sciences Ltd. is the 10 percent owner of Urovant Sciences Ltd. Other key executives at Urovant Sciences Ltd include SVP & Commercial & USI Walt Johnston , CMO/Urovant Sciences & Inc. Haag-molkenteller Cornelia , and PFO;CFO/Urovant Sciences & Inc. Ajay Bansal .

Urovant Sciences Ltd (UROV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Urovant Sciences Ltd (UROV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Urovant Sciences Ltd (UROV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Urovant Sciences Ltd (UROV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Urovant Sciences Ltd Insider Transactions

No Available Data

What does Arbutus Biopharma Corp do?

Who are the key executives at Arbutus Biopharma Corp?

Roivant Sciences Ltd. is the 10 percent owner of Arbutus Biopharma Corp. Other key executives at Arbutus Biopharma Corp include Chief Financial Officer David C Hastings , Chief Business Officer Michael J. Mcelhaugh , and Chief Scientific Officer Michael J. Sofia .

Arbutus Biopharma Corp (ABUS) Insider Trades Summary

Over the past 18 months, Roivant Sciences Ltd. made no insider transaction in Arbutus Biopharma Corp (ABUS). Other recent insider transactions involving Arbutus Biopharma Corp (ABUS) include a net sale of 10,164 shares made by Michael J. Mcelhaugh , a net sale of 9,982 shares made by Michael J. Sofia , and a net sale of 9,593 shares made by David C Hastings .

In summary, during the past 3 months, insiders sold 0 shares of Arbutus Biopharma Corp (ABUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 42,943 shares of Arbutus Biopharma Corp (ABUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 42,943 shares.

Arbutus Biopharma Corp (ABUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arbutus Biopharma Corp Insider Transactions

No Available Data

What does Immunovant Inc do?

Who are the key executives at Immunovant Inc?

Roivant Sciences Ltd. is the 10 percent owner of Immunovant Inc. Other key executives at Immunovant Inc include director & Chief Executive Officer Peter Salzmann , Chief Legal Officer Mark S. Levine , and Chief Financial Officer Eva Renee Barnett .

Immunovant Inc (IMVT) Insider Trades Summary

Over the past 18 months, Roivant Sciences Ltd. made 1 insider transaction in Immunovant Inc (IMVT) with a net purchase of 1,526,316. Other recent insider transactions involving Immunovant Inc (IMVT) include a net sale of 416,806 shares made by Peter Salzmann , a net sale of 76,397 shares made by Eva Renee Barnett , and a net sale of 66,441 shares made by Mark S. Levine .

In summary, during the past 3 months, insiders sold 66,195 shares of Immunovant Inc (IMVT) in total and bought 0 shares, with a net sale of 66,195 shares. During the past 18 months, 717,263 shares of Immunovant Inc (IMVT) were sold and 1,526,316 shares were bought by its insiders, resulting in a net purchase of 809,053 shares.

Immunovant Inc (IMVT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunovant Inc Insider Transactions

No Available Data

Roivant Sciences Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Roivant Sciences Ltd.. You might contact Roivant Sciences Ltd. via mailing address: Clarendon House, 2 Church Street, Hamilton D0 Hm11.

Discussions on Roivant Sciences Ltd.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.